智通财经APP获悉，诺诚健华(09969)盘中涨超5%，截至发稿，涨3.29%，报10.69港元，成交额4304.89万港元。
消息面上，6月18日，据诺诚健华官微消息，公司宣布，在2026欧洲血液学协会(EHA)年会最高级别的全体大会上，坦昔妥单抗联合疗法全球III期frontMIND研究结果以口头报告形式重磅发布。
结果显示，相较于现有一线标准疗法R-CHOP方案，坦昔妥单抗联合来那度胺和R-CHOP方案(Tafa-Len-R-CHOP)的研究结果展示无进展生存期(PFS)大幅改善，具有显著统计学意义和临床价值，有望为高危弥漫大B细胞淋巴瘤(DLBCL)和高级别B细胞淋巴瘤(HGBL)患者提供全新的一线标准治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.